Sfoglia per Autore
Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy
2015 R. D’Ambrosio, C. Della Corte, M. Colombo
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C
2015 R. D'Ambrosio, A. Aghemo, M. Colombo
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity
2015 C. Cheroni, L. Donnici, A. Aghemo, F. Balistreri, A. Bianco, V. Zanoni, M. Pagani, R. Soffredini, R. D'Ambrosio, M.G. Rumi, M. Colombo, S. Abrignani, P. Neddermann, R. De Francesco
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
2015 M. Milano, A. Aghemo, R.M. Mancina, J. Fischer, P. Dongiovanni, S. De Nicola, A.L. Fracanzani, R. D'Ambrosio, M. Maggioni, R. De Francesco, S. Fargion, T. Berg, F. Stickel, J. Hampe, S. Romeo, M. Colombo, L. Valenti
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon
2016 R. D'Ambrosio, E. Degasperi, A. Aghemo, M. Fraquelli, P. Lampertico, M.G. Rumi, F. Facchetti, E. Grassi, G. Casazza, W. Rosenberg, P. Bedossa, M. Colombo
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin
2016 E. Degasperi, S. DE NICOLA, M. Rumi, R. D'Ambrosio
Editorial : good news to patients with thalassaemia HCV clearance made easy with direct-acting antivirals
2017 R. D'Ambrosio, P. Lampertico
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis
2017 A. Tripodi, R. D'Ambrosio, L. Padovan, G. Tosetti, A. Aghemo, M. Primignani, V. Chantarangkul, F. Peyvandi, M. Colombo
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies
2017 R. Origa, M.L. Ponti, A. Filosa, A. Galeota Lanza, A. Piga, G.M. Saracco, V. Pinto, A. Picciotto, P. Rigano, S. Madonia, R. Rosso, D. D'Ascola, M.D. Cappellini, R. D'Ambrosio, I. Tartaglione, L. De Franceschi, B. Gianesin, V. Di Marco, G.L. Forni
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
2018 E. Degasperi, A. Aghemo, S. Paolucci, R. D'Ambrosio, M. Borghi, R. Perbellini, F. Novazzi, S. De Nicola, G. Lunghi, F. Baldanti, P. Lampertico
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression
2018 R. D'Ambrosio, A. Aghemo, M.G. Rumi, E. Degasperi, A. Sangiovanni, M. Maggioni, M. Fraquelli, R. Perbellini, W. Rosenberg, P. Bedossa, M. Colombo, P. Lampertico
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy
2019 L. Pasulo, M. Gambato, A. Spinetti, R. D'Ambrosio, M. Puoti, A. Ciancio, V. Di Marco, V. Calvaruso, P. Colombatto, M. Brunetto, M. Schiavini, P. Fabris, P. Sacchi, R. Gulminetti, G. Carolo, P. Scotton, C. Pozzan, M. Vinci, M. Vigano, A. Lombardi, S. Lo Bello, M. Zuin, A. Aghemo, M.G. Rumi, M. Carrara, V. Manfrin, C. Uberti-Foppa, S. Panese, V. Paon, A. Pan, O. Spinelli, A.D. Monforte, A. Colli, G. Spinzi, F.P. Russo, L. Chemello, V. Vincenzi, P. Grossi, E. Buscarini, G. Cardaci, A. Soria, B. Menzaghi, M. Mendeni, R. Soffredini, M. Colpani, S. Zaltron, A. Gori, P. Del Poggio, A. Giorgini, G. Cologni, F. Cartabellotta, F. Di Lorenzo, I. Cacciola, A. Albanese, M.A. Di Rosolini, A. Digiacomo, A. Capretti, M. Memoli, C. Rossi, L. Cavalletto, F. Capra, A.E. Colombo, C. Dibenedetto, C.F. Magni, F. Noventa, P. Lampertico, F. Castelli, A. Alberti, S. Fagiuoli
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients
2019 R. D'Ambrosio, M. Vinci, M. Franchina, L. Parlati, S. Zaltron, L. Pasulo, M. Campise, P. Messa, S. Pol, P. Lampertico
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease
2019 G. Tosetti, M. Primignani, V. La Mura, R. D'Ambrosio, E. Degasperi, N. Mezzina, M. Viganò, M. Rumi, A.L. Fracanzani, R. Lombardi, S. Fargion, M. Fraquelli, A. Aghemo, P. Lampertico
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms
2019 R.E. Sharkawy, A. Bayoumi, M. Metwally, A. Mangia, T. Berg, M. Romero-Gomez, M.L. Abate, W.L. Irving, D. Sheridan, G.J. Dore, U. Spengler, P. Lampertico, E. Bugianesi, M. Weltman, L. Mollison, W. Cheng, S. Riordan, R. Santoro, R. Gallego-Durán, J. Fischer, J. Nattermann, R. D’Ambrosio, D. Mcleod, E. Powell, O. Latchoumanin, K. Thabet, M.A.M. Najim, M.W. Douglas, C. Liddle, L. Qiao, J. George, M. Eslam, R. White, A. Rojas, M. Bassendine, C. Rosso, L. Mezzabotta, R. Leung, B. Malik, G. Matthews, J. Grebely, V. Fragomeli, J.R. Jonsson
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
2019 R. D'Ambrosio, L. Pasulo, M. Puoti, M. Vinci, M. Schiavini, S. Lazzaroni, A. Soria, F. Gatti, B. Menzaghi, F. Capelli, M.G. Rumi, L. Morini, A. Giorgini, M.G. Pigozzi, A. Rossini, F. Maggiolo, A. Pan, M. Memoli, O. Spinelli, P. Del Poggio, V. Saladino, A. Spinetti, A. De Bona, A. Capretti, C. Uberti-Foppa, P. Bonfanti, N. Terreni, F. Menozzi, A.E. Colombo, O. Giglio, R. Centenaro, C. Baiguera, V. Picciotto, S. Landonio, A. Gori, C. Magnani, F. Noventa, S. Paolucci, P. Lampertico, S. Fagiuoli, A. Aghemo, M. Borghi
Impact of HCV and Direct Acting Antivirals on Kidney Recipients: a retrospective study
2019 M. Gendia, P. Lampertico, C.M. Alfieri, R. D'Ambrosio, M.T. Gandolfo, M.R. Campise, F. Fabrizi, P. Messa
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis
2019 G. Sigon, R. D'Ambrosio, M. Clerici, G. Pisano, V. Chantarangkul, R. Sollazzi, R. Lombardi, F. Peyvandi, P. Lampertico, S. Fargion, A. Tripodi, A.L. Fracanzani
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
2020 C. Bianco, O. Jamialahmadi, S. Pelusi, G. Baselli, P. Dongiovanni, I. Zanoni, L. Santoro, S. Maier, A. Liguori, M. Meroni, V. Borroni, R. D'Ambrosio, R. Spagnuolo, A. Alisi, A. Federico, E. Bugianesi, S. Petta, L. Miele, U. Vespasiani-Gentilucci, Q.M. Anstee, F. Stickel, J. Hampe, J. Fischer, T. Berg, A.L. Fracanzani, G. Soardo, H. Reeves, D. Prati, S. Romeo, L. Valenti
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis
2020 A. Sangiovanni, E. Alimenti, R. Gattai, R. Filomia, E. Parente, L. Valenti, L. Marzi, G. Pellegatta, G. Borgia, M. Gambato, N. Terreni, I. Serio, L. Belli, F. Oliveri, S. Maimone, M. Brunacci, R. D'Ambrosio, L.V. Forzenigo, F.P. Russo, M. Rumi, M. Barone, A.L. Fracanzani, G. Raimondo, E.G. Giannini, M.R. Brunetto, E. Villa, E. Biganzoli, M. Colombo, P. Lampertico
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile